Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients

BACKGROUND: Early ibrutinib trials showed an association between ibrutinib use and risk of bleeding and atrial fibrillation (AF) in younger chronic lymphocytic leukemia (CLL) patients. Little is known about these adverse events in older CLL patients and whether increased AF rates are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Diamond, Akiva, Bensken, Wyatt P., Vu, Long, Dong, Weichuan, Koroukian, Siran M., Caimi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Mini-Focus Issue: Bleeding, Thrombosis, and Atrial Fibrillation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152196/
https://www.ncbi.nlm.nih.gov/pubmed/37144107
http://dx.doi.org/10.1016/j.jaccao.2023.02.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152196/
https://www.ncbi.nlm.nih.gov/pubmed/37144107
http://dx.doi.org/10.1016/j.jaccao.2023.02.001

Ejemplares similares